{"count": 16, "results": [{"_id": "34439918", "pmid": 34439918, "pmcid": "PMC8392201", "title": "Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes", "journal": "Biomolecules", "authors": ["Wang JL", "Tsai YT", "Lin CH", "Cidem A", "Staniczek T", "Chang GR", "Yen CC", "Chen W", "Chong KY", "Chen CM"], "date": "2021-08-21T00:00:00Z", "doi": "10.3390/biom11081252", "meta_date_publication": "2021 Aug 21", "meta_volume": "11", "meta_issue": "8", "meta_pages": "", "score": 50278.777, "text_hl": "Benefits of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Combined with @CHEMICAL_Pemetrexed @CHEMICAL_MESH:D000068437 @@@Pemetrexed@@@-Based @CHEMICAL_Platinum @CHEMICAL_MESH:D010984 @@@Platinum@@@ Doublets as a First-Line Therapy for Advanced @<m>DISEASE_Adenocarcinoma_of_Lung</m> @DISEASE_MESH:D000077192 @@@Lung Adenocarcinoma@@@ @SPECIES_9606 @@@Patients@@@ with @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes@@@", "citations": {"NLM": "Wang JL, Tsai YT, Lin CH, Cidem A, Staniczek T, Chang GR, Yen CC, Chen W, Chong KY, Chen CM. Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes Biomolecules. 2021 Aug 21;11(8):. PMID: 34439918", "BibTeX": "@article{34439918, title={Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes}, author={Wang JL and Tsai YT and Lin CH and Cidem A and Staniczek T and Chang GR and Yen CC and Chen W and Chong KY and Chen CM}, journal={Biomolecules}, volume={11}, number={8}}"}}, {"_id": "40183277", "pmid": 40183277, "title": "Metformin Inhibits the Development of Lung Adenocarcinoma by Regulating the Expression of CCNA2 via E2F1.", "journal": "Comb Chem High Throughput Screen", "authors": ["Wang L", "Huang Y", "Tian M", "Hu M", "Zhang K", "Lian C", "Wang X", "Zhang J"], "date": "2025-04-03T00:00:00Z", "doi": "10.2174/0113862073348968241101112455", "meta_date_publication": "2025 Apr 3", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50260.324, "text_hl": "METHODS: The key genes and signaling pathways of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MET@@@ acting on @<m>DISEASE_Adenocarcinoma_of_Lung</m> @DISEASE_MESH:D000077192 @@@LUAD@@@ were screened by bioinformatics, and the effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MET@@@ on @<m>DISEASE_Adenocarcinoma_of_Lung</m> @DISEASE_MESH:D000077192 @@@LUAD@@@ cell proliferation, invasion, migration, and apoptosis were detected. ", "citations": {"NLM": "Wang L, Huang Y, Tian M, Hu M, Zhang K, Lian C, Wang X, Zhang J. Metformin Inhibits the Development of Lung Adenocarcinoma by Regulating the Expression of CCNA2 via E2F1. Comb Chem High Throughput Screen. 2025 Apr 3;():. PMID: 40183277", "BibTeX": "@article{40183277, title={Metformin Inhibits the Development of Lung Adenocarcinoma by Regulating the Expression of CCNA2 via E2F1.}, author={Wang L and Huang Y and Tian M and Hu M and Zhang K and Lian C and Wang X and Zhang J}, journal={Comb Chem High Throughput Screen}}"}}, {"_id": "39194678", "pmid": 39194678, "title": "Astragalus Polysaccharides and Metformin May Have Synergistic Effects on the Apoptosis and Ferroptosis of Lung Adenocarcinoma A549 Cells.", "journal": "Curr Issues Mol Biol", "authors": ["Lee IY", "Wang TC", "Kuo YJ", "Shih WT", "Yang PR", "Hsu CM", "Lin YS", "Kuo RS", "Wu CY"], "date": "2024-07-23T00:00:00Z", "doi": "10.3390/cimb46080461", "meta_date_publication": "2024 Jul 23", "meta_volume": "46", "meta_issue": "8", "meta_pages": "7782-7794", "score": 50260.316, "text_hl": "Astragalus Polysaccharides and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ May Have Synergistic Effects on the Apoptosis and Ferroptosis of @<m>DISEASE_Adenocarcinoma_of_Lung</m> @DISEASE_MESH:D000077192 @@@Lung Adenocarcinoma@@@ @CELLLINE_CVCL:0023 @@@A549@@@ Cells.", "citations": {"NLM": "Lee IY, Wang TC, Kuo YJ, Shih WT, Yang PR, Hsu CM, Lin YS, Kuo RS, Wu CY. Astragalus Polysaccharides and Metformin May Have Synergistic Effects on the Apoptosis and Ferroptosis of Lung Adenocarcinoma A549 Cells. Curr Issues Mol Biol. 2024 Jul 23;46(8):7782-7794. PMID: 39194678", "BibTeX": "@article{39194678, title={Astragalus Polysaccharides and Metformin May Have Synergistic Effects on the Apoptosis and Ferroptosis of Lung Adenocarcinoma A549 Cells.}, author={Lee IY and Wang TC and Kuo YJ and Shih WT and Yang PR and Hsu CM and Lin YS and Kuo RS and Wu CY}, journal={Curr Issues Mol Biol}, volume={46}, number={8}, pages={7782-7794}}"}}, {"_id": "38008395", "pmid": 38008395, "title": "Targeting TAM-secreted S100A9 effectively enhances the tumor-suppressive effect of metformin in treating lung adenocarcinoma.", "journal": "Cancer Lett", "authors": ["Sui Q", "Hu Z", "Liang J", "Lu T", "Bian Y", "Jin X", "Li M", "Huang Y", "Yang H", "Wang Q", "Lin Z", "Chen Z", "Zhan C"], "date": "2023-11-25T00:00:00Z", "doi": "10.1016/j.canlet.2023.216497", "meta_date_publication": "2023 Nov 25", "meta_volume": "581", "meta_issue": "", "meta_pages": "216497", "score": 50258.66, "text_hl": "Targeting TAM-secreted @GENE_S100A9 @GENE_6280 @@@S100A9@@@ effectively enhances the @DISEASE_Neoplasms @DISEASE_MESH:D009369 @@@tumor@@@-suppressive effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in treating @<m>DISEASE_Adenocarcinoma_of_Lung</m> @DISEASE_MESH:D000077192 @@@lung adenocarcinoma@@@.", "citations": {"NLM": "Sui Q, Hu Z, Liang J, Lu T, Bian Y, Jin X, Li M, Huang Y, Yang H, Wang Q, Lin Z, Chen Z, Zhan C. Targeting TAM-secreted S100A9 effectively enhances the tumor-suppressive effect of metformin in treating lung adenocarcinoma. Cancer Lett. 2023 Nov 25;581():216497. PMID: 38008395", "BibTeX": "@article{38008395, title={Targeting TAM-secreted S100A9 effectively enhances the tumor-suppressive effect of metformin in treating lung adenocarcinoma.}, author={Sui Q and Hu Z and Liang J and Lu T and Bian Y and Jin X and Li M and Huang Y and Yang H and Wang Q and Lin Z and Chen Z and Zhan C}, journal={Cancer Lett}, volume={581}, pages={216497}}"}}, {"_id": "35603556", "pmid": 35603556, "pmcid": "PMC9275981", "title": "Metformin suppresses lung adenocarcinoma by downregulating long non-coding RNA (lncRNA) AFAP1-AS1 and secreted phosphoprotein 1 (SPP1) while upregulating miR-3163", "journal": "Bioengineered", "authors": ["Qiu C", "Li C", "Zheng Q", "Fang S", "Xu J", "Wang H", "Guo H"], "date": "2022-05-01T00:00:00Z", "doi": "10.1080/21655979.2021.2005981", "meta_date_publication": "2022 May", "meta_volume": "13", "meta_issue": "5", "meta_pages": "11987-12002", "score": 50256.684, "text_hl": "...@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ inhibits the @<m>DISEASE_Adenocarcinoma_of_Lung</m> @DISEASE_MESH:D000077192 @@@LUAD@@@ cell proliferation, migration and invasion. ", "citations": {"NLM": "Qiu C, Li C, Zheng Q, Fang S, Xu J, Wang H, Guo H. Metformin suppresses lung adenocarcinoma by downregulating long non-coding RNA (lncRNA) AFAP1-AS1 and secreted phosphoprotein 1 (SPP1) while upregulating miR-3163 Bioengineered. 2022 May;13(5):11987-12002. PMID: 35603556", "BibTeX": "@article{35603556, title={Metformin suppresses lung adenocarcinoma by downregulating long non-coding RNA (lncRNA) AFAP1-AS1 and secreted phosphoprotein 1 (SPP1) while upregulating miR-3163}, author={Qiu C and Li C and Zheng Q and Fang S and Xu J and Wang H and Guo H}, journal={Bioengineered}, volume={13}, number={5}, pages={11987-12002}}"}}, {"_id": "40935675", "pmid": 40935675, "title": "Genomic Profiling Identified a Mutational Signature Related to Female in Non-Smoking Lung Adenocarcinoma.", "journal": "Cancer Res Treat", "authors": ["Zhuang J", "Yang Y", "Chen X", "Zheng G", "Shen X", "He F", "Xie B"], "date": "2025-09-11T00:00:00Z", "doi": "10.4143/crt.2025.489", "meta_date_publication": "2025 Sep 11", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50248.324, "text_hl": "@CELLLINE_CVCL:Z232 @@@S2@@@-enriched group had higher mutation rate of @GENE_EGFR @GENE_1956 @@@EGFR@@@ (p=0.003) and more drug sensitivity to @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (p=0.035). Conclusion: We identified a new mutational signature (@CELLLINE_CVCL:Z232 @@@S2@@@) which is most enriched in @<m>DISEASE_Adenocarcinoma_of_Lung</m> @DISEASE_MESH:D000077192 @@@LUAD@@@ in non-smokers and related to female and low-TMB. ", "citations": {"NLM": "Zhuang J, Yang Y, Chen X, Zheng G, Shen X, He F, Xie B. Genomic Profiling Identified a Mutational Signature Related to Female in Non-Smoking Lung Adenocarcinoma. Cancer Res Treat. 2025 Sep 11;():. PMID: 40935675", "BibTeX": "@article{40935675, title={Genomic Profiling Identified a Mutational Signature Related to Female in Non-Smoking Lung Adenocarcinoma.}, author={Zhuang J and Yang Y and Chen X and Zheng G and Shen X and He F and Xie B}, journal={Cancer Res Treat}}"}}, {"_id": "38478170", "pmid": 38478170, "title": "FAM83B regulates mitochondrial metabolism and anti-apoptotic activity in pulmonary adenocarcinoma.", "journal": "Apoptosis", "authors": ["Wang J", "Li P", "Sun L", "Zhang J", "Yue K", "Wang Y", "Wu X"], "date": "2024-03-13T00:00:00Z", "doi": "10.1007/s10495-024-01944-7", "meta_date_publication": "2024 Mar 13", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50244.504, "text_hl": "Consequently, this ultimately confers resistance to chemotherapy in @<m>DISEASE_Adenocarcinoma_of_Lung</m> @DISEASE_MESH:D000077192 @@@LUAD@@@. Furthermore, the administration of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, which blocks mitochondrial oxidative phosphorylation (OXPHOS), can restore sensitivity to drug resistance in @<m>DISEASE_Adenocarcinoma_of_Lung</m> @DISEASE_MESH:D000077192 @@@LUAD@@@. ", "citations": {"NLM": "Wang J, Li P, Sun L, Zhang J, Yue K, Wang Y, Wu X. FAM83B regulates mitochondrial metabolism and anti-apoptotic activity in pulmonary adenocarcinoma. Apoptosis. 2024 Mar 13;():. PMID: 38478170", "BibTeX": "@article{38478170, title={FAM83B regulates mitochondrial metabolism and anti-apoptotic activity in pulmonary adenocarcinoma.}, author={Wang J and Li P and Sun L and Zhang J and Yue K and Wang Y and Wu X}, journal={Apoptosis}}"}}, {"_id": "35918384", "pmid": 35918384, "pmcid": "PMC9345949", "title": "Transcriptomic data exploration of consensus genes and molecular mechanisms between chronic obstructive pulmonary disease and lung adenocarcinoma", "journal": "Sci Rep", "authors": ["Zhang S", "Pang K", "Feng X", "Zeng Y"], "date": "2022-08-02T00:00:00Z", "doi": "10.1038/s41598-022-17552-x", "meta_date_publication": "2022 Aug 2", "meta_volume": "12", "meta_issue": "1", "meta_pages": "13214", "score": 50242.992, "text_hl": "In the @DISEASE_Pulmonary_Disease_Chronic_Obstructive @DISEASE_MESH:D029424 @@@COPD@@@-@<m>DISEASE_Adenocarcinoma_of_Lung</m> @DISEASE_MESH:D000077192 @@@LUAD@@@ turquoise module, @CHEMICAL_Bortezomib @CHEMICAL_MESH:D000069286 @@@bortezomib@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ were identified as the main drug- targets. ", "citations": {"NLM": "Zhang S, Pang K, Feng X, Zeng Y. Transcriptomic data exploration of consensus genes and molecular mechanisms between chronic obstructive pulmonary disease and lung adenocarcinoma Sci Rep. 2022 Aug 2;12(1):13214. PMID: 35918384", "BibTeX": "@article{35918384, title={Transcriptomic data exploration of consensus genes and molecular mechanisms between chronic obstructive pulmonary disease and lung adenocarcinoma}, author={Zhang S and Pang K and Feng X and Zeng Y}, journal={Sci Rep}, volume={12}, number={1}, pages={13214}}"}}, {"_id": "35024769", "pmid": 35024769, "title": "Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial.", "journal": "JAMA Oncol", "authors": ["Arrieta O", "Zatarain-Barrón ZL", "Turcott JG", "Barrón F", "Yendamuri S", "Cardona AF", "Rosell R"], "date": "2022-03-01T00:00:00Z", "doi": "10.1001/jamaoncol.2021.7015", "meta_date_publication": "2022 Mar 1", "meta_volume": "8", "meta_issue": "3", "meta_pages": "477-479", "score": 50242.508, "text_hl": "Association of BMI With Benefit of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Plus @GENE_EGFR @GENE_1956 @@@Epidermal Growth Factor Receptor@@@-@GENE_TXK @GENE_7294 @@@Tyrosine Kinase@@@ Inhibitors in @SPECIES_9606 @@@Patients@@@ With Advanced @<m>DISEASE_Adenocarcinoma_of_Lung</m> @DISEASE_MESH:D000077192 @@@Lung Adenocarcinoma@@@: A Secondary Analysis of a Phase 2 Randomized Clinical Trial.", "citations": {"NLM": "Arrieta O, Zatarain-Barrón ZL, Turcott JG, Barrón F, Yendamuri S, Cardona AF, Rosell R. Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022 Mar 1;8(3):477-479. PMID: 35024769", "BibTeX": "@article{35024769, title={Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma: A Secondary Analysis of a Phase 2 Randomized Clinical Trial.}, author={Arrieta O and Zatarain-Barrón ZL and Turcott JG and Barrón F and Yendamuri S and Cardona AF and Rosell R}, journal={JAMA Oncol}, volume={8}, number={3}, pages={477-479}}"}}, {"_id": "31523021", "pmid": 31523021, "title": "Metformin plus EGFR TKIs for lung adenocarcinoma.", "journal": "Lancet Oncol", "authors": ["Stirrups R"], "date": "2019-10-01T00:00:00Z", "doi": "10.1016/S1470-2045(19)30571-6", "meta_date_publication": "2019 Oct", "meta_volume": "20", "meta_issue": "10", "meta_pages": "e563", "score": 50070.36, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ plus @GENE_EGFR @GENE_1956 @@@EGFR@@@ TKIs for @<m>DISEASE_Adenocarcinoma_of_Lung</m> @DISEASE_MESH:D000077192 @@@lung adenocarcinoma@@@.", "citations": {"NLM": "Stirrups R. Metformin plus EGFR TKIs for lung adenocarcinoma. Lancet Oncol. 2019 Oct;20(10):e563. PMID: 31523021", "BibTeX": "@article{31523021, title={Metformin plus EGFR TKIs for lung adenocarcinoma.}, author={Stirrups R}, journal={Lancet Oncol}, volume={20}, number={10}, pages={e563}}"}}]}